In light of the pandemic situation events until September 2021 are cancelled. We will inform customers directly when the events are rescheduled.    
COVID CANCELLED: Project Management in Human Resources,   Boston MA, Jan 6-8, 2021
COVID CANCELLED: InterDrone, The International Drone Conference,   Cambridge MA, Jan 11-13, 2021
COVID CANCELLED: Supplier Management for Medical Device Manufacturers,   Cambridge MA, Feb 2-4, 2021
COVID CANCELLED: US Immigration Compliance Strategies,   Boston MA, Feb 15-18, 2021
COVID CANCELLED: Project Management Training,   Boston MA, Mar 3-5, 2021
COVID CANCELLED: Internal Audit, Fraud Risk Assessment Workshop,   Boston MA, Mar 22-25, 2021
COVID CANCELLED: Agile / Scrum Training,   Boston MA, Apr 12-14, 2021
COVID CANCELLED: Validation, Verification and Transfer of Analytical Methods,   Boston MA, Apr 19-21, 2021
COVID CANCELLED: Computer System Validation - Reduce Costs and Avoid 483s,   Boston MA, May 10-12, 2021
COVID CANCELLED: SharePoint Technology Conference,   Boston MA, May 26-28, 2021
COVID CANCELLED: Employment Laws Certificate Program,   Boston MA, Jun 7-9, 2021
Following events are tentatively planned but may be rescheduled, based on CDC guidelines or attendee registration interest .    
TENTATIVE: 21 CFR Part 11 Compliance,   Boston MA, Sep 22-24, 2021
TENTATIVE: Quality Control Laboratory Compliance,   Boston MA, Oct 6-8, 2021
TENTATIVE: Analytical Instrument Qualification and System Validation,   Boston MA, Nov 15-17, 2021
TENTATIVE: FDA's New Import Program for 2021,   Boston MA, Dec 7-9, 2021

Boston Professional Events List

2nd Gene Therapy Comparability

Mar 29, 2022 - 09:00 AM - Apr 01, 04:30 PM
Hanson Wade
Hyatt Regency Boston
1, Ave

De Lafayette Boston,
ZIP: 02111
Phone: +44 020 3141 8700

Ticket Price: USD 2999.00 to USD 5793.00

The Gene Therapy Comparability Summit returns for the second year providing you with all the practical insights to optimize your gene therapy comparability approach.

In the context of scaling up gene therapy development to achieve commercial goals and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Comparability Summit will unite large pharma and innovative biotechs to ensure you can establish comparability at every stage of development, supporting a seamless transition to the larger scales required for commercialization.

Focused specifically on enhancing your gene therapy comparability approach, this event will ensure you can maintain safety, quality, consistency and efficacy while adapting manufacturing processes, methods and platforms, to satisfy regulatory demands and avoid costly delays to clinical programs.

Across four days of curated content, incorporating detailed case studies from leading CMC, Regulatory, Analytical and Process Development experts, this is your opportunity to gain a hands-on, practical insight into exactly what it takes to execute successful comparability studies.

Brochure: https://go.evvnt.com/928130-2?pid=1052
Tickets: https://go.evvnt.com/928130-3?pid=1052

Drug Developer Pricing - FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Comparability Day: USD 4793.00,
Drug Developer Pricing - 2 Day Conference + Workshop Day OR Comparability Day: USD 3896.00,
Drug Developer Pricing - 2 Day Conference: USD 2999.00,
Standard Pricing - FULL ACCESS PASS: 2 Day Conference + Workshop Day AND Comparability Day: USD 5793.00,
Standard Pricing - 2 Day Conference + Workshop Day OR Comparability Day: USD 4896.00,
Standard Pricing - 2 Day Conference: USD 3999.00

Speaker Details

Janet Glassford, Quality Assessor, MHRA, Joshua Kidder, Director of Quality, Control Ultragenyx, Van Hoang, Head of Analytical and Quality Control, Spark Therapeutics, Ilya Shestopalov, Director and Analytical Product Lead, Bluebird Bio, Meghan Brown, Executive Director, Regulatory Affairs, CMC, Sarepta Therapeutics, Sarang Brahma, Scientist III, AskBio, Josephine Lembong, Manager, Science and Industry Affairs, Alliance for Regenerative Medicine, Nina Liu, Staff Scientist, Regeneron, Thomas Powers, Principal Scientist, Pfizer, Dawn Henke, Senior Scientific Program Manager, Standards Coordinating Body, Michael Rosconi, Associate Director, Regeneron, Santoshkumar Khatwani, Director Analytical Development, Sangamo Therapeutics, Kun Lu, Senior Staff Scientist, Regeneron, Rachael Ahern, Associate Director, Quality Control, Tessera Therapeutics, Susan Sleep, Director Analytical Development, AGTC, Alexis Behra, Quality by Design and Risk Manager, Cellectis, Cynthia N. Brysch, Head of CQA, Vertex Pharmaceuticals, Kyle Grant, Director of Vector Production, Voyager Therapeutics, Greg Hoffman, Vice President Platform and Discovery, Arbor Biotechnology, Jeremy Johnston, Director, Analytical Department, AskBio, Richard K. Burdick, Principal Consultant, Ann F Durbin, Associate Director, Assay Development, Abeona Therapeutics, Steve Soltys, VP, Process Development, Kriya Therapeutics, William Werner, Sr. Director Analytical Assay development, Astellas Gene Therapies, Allan B. Dietz, Ph.D. Director, Immune Progenitor and Stem Cell lab (IMPACT), Associate Professor of Laboratory Medicine, Associate Professor of Immunology, Mayo Clinic, Arnaud Deladeriere, Director of Process Development, Triumvira, Markus Haindl, Head Gene Therapy Technical Development, Roche, Omar Tounekti, Manager, Gene Therapies Division in the Biologic and Radiopharmaceutical Drugs Directorate (BRDD), Health Canada, Yoko Momonoi Head, Global CMC Regulatory Affairs, Takeda, Wyatt Technologies, Qiagen, Touchlight AAV

Event Categories
Keywords: conference , Health , science , Medicine


Events Calendar

27 28 1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31 1 2


VIP Life Time Subscription to our Newsletters!